Revolutionizing Clinical Trials for Alzheimer’s: An International Perspective
Welcome & introduction

Pierre Meulien
Executive Director
Innovative Medicines Initiative
The panel

- Pierre Meulien | Innovative Medicines Initiative
- Simon Lovestone | University of Oxford
- Paul Stoffels | Johnson & Johnson
- Heather Snyder | Alzheimer’s Association
Imagine

People living with dementia (millions)

- 2015: 46.8 million
- 2030: 74.7 million
- 2050: 131.5 million
IMAGINE

1 500
IMAGINE

£ £ £ € € €

$ $ $ ¥ ¥ ¥
Because...

• the therapeutic targets may have been incorrect
• treatments may have been given too late in the disease process
• the current clinical trial process for developing proof of concept is inefficient
WE NEED TO DO THINGS DIFFERENTLY

• Focus on prevention, before symptoms appear
• Use adaptive trial design
• Initiatives underway in Europe and US
THANK YOU!

Pierre Meulien
Executive Director, Innovative Medicines Initiative

www.imi.europa.eu | @IMI_JU